COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=49317

Zhuoli Zhang

zhuoli.zhang@126.com

2020-02-11

Recruiting

RCT

Randomized

Parallel

Open label

single-center

Treatment

Patients with novel coronavirus infection who agreed to participate in this trial and signed the informed consent form. The diagnose criteria was according to Diagnostic and treatment protocol of COVID-19 pneumonia published by Chinese General Office of National Health Committee(6th and further edition).

Patients who is enrolled in other clinical trial who had diagnosed as macular degeneration of retinawere or defects of visual field, who was allergic to 4-aminoquinoline compounds or is prescribed any drug had interactions with hydrocholoroquine emergency or critically ill patients who can not received oral drugs pregnancy or lactation severe heart disease, digestive disease,neurological or ocular disease,or porphyrin, WBC less than 2.0*10^9/L,hemoglobin 60g/L,liver enzyme or creatine higher than 3 times of ULT,or heart marker elevated, unsuitable to participate this trial by investigator or in other special circumstances.

2

The First Hospital of Peking University

16

99

China

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

78

oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 4

[{"arm_notes": "", "treatment_id": 607, "treatment_name": "Hydroxychloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]